|
|
Article: Sleep aid promises prescribing flexiblity without rebound insomnia, residual drowsiness
- Article from:
- Formulary
- Article date:
- October 1, 1998
- Author:
CopyrightCopyright Advanstar Communications, Inc. Oct 1998. Provided by ProQuest LLC. (Hide copyright information)
|
The investigational GABAA/benzodiazepine receptor agonist zaleplon may hold advantages over other sleep aids in flexibility of use and avoidance of rebound insomnia and next-day drowsiness, according to several recently presented studies.
The largest of the studies of the short-acting sedative hypnotic was a multicenter, double-blind, phase III trial reported at the 12th annual meeting of the Association of Professional Sleep Societies (APSS) in New Orleans. The study's 598 patients with insomnia were randomized to receive either zaleplon (5, 10, or 20 mg), market leader zolpidem (10 mg), or placebo for 28 days. Endpoints were subjective and included time to sleep onset, sleep quality, and ...